CY1113310T1 - Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων - Google Patents

Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων

Info

Publication number
CY1113310T1
CY1113310T1 CY20121101051T CY121101051T CY1113310T1 CY 1113310 T1 CY1113310 T1 CY 1113310T1 CY 20121101051 T CY20121101051 T CY 20121101051T CY 121101051 T CY121101051 T CY 121101051T CY 1113310 T1 CY1113310 T1 CY 1113310T1
Authority
CY
Cyprus
Prior art keywords
nogo
specialties
pumped
specific
pharmaceutical uses
Prior art date
Application number
CY20121101051T
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Paul Andrew Hamblin
Farhana Hussain
Alan Peter Lewis
Ruth Mcadam
Rabinder Prinjha
Paul Wilson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0513766A external-priority patent/GB0513766D0/en
Priority claimed from GB0525448A external-priority patent/GB0525448D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CY1113310T1 publication Critical patent/CY1113310T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε αντισώματα προς NOGO, φαρμακοτεχνικές μορφές που περιέχουν αυτά και στη χρήση τέτοιων αντισωμάτων στη θεραπεία ή/και την προφύλαξη νευρολογικών ασθενειών/διαταραχών.
CY20121101051T 2005-07-05 2012-11-05 Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων CY1113310T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0513766A GB0513766D0 (en) 2005-07-05 2005-07-05 Immunoglobulins
GB0525448A GB0525448D0 (en) 2005-12-14 2005-12-14 Immunoglobulins
EP06776123A EP1899377B1 (en) 2005-07-05 2006-07-03 Humanised antibodies specific for nogo-a and phrarmaceutical uses thereof

Publications (1)

Publication Number Publication Date
CY1113310T1 true CY1113310T1 (el) 2016-04-13

Family

ID=37604821

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101051T CY1113310T1 (el) 2005-07-05 2012-11-05 Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων

Country Status (22)

Country Link
EP (1) EP1899377B1 (el)
JP (1) JP2009500363A (el)
KR (1) KR20080030960A (el)
AU (1) AU2006265276B2 (el)
BR (1) BRPI0612734A2 (el)
CA (1) CA2614076A1 (el)
CR (1) CR9623A (el)
CY (1) CY1113310T1 (el)
DK (1) DK1899377T3 (el)
EA (1) EA014291B1 (el)
ES (1) ES2391902T3 (el)
HK (1) HK1115598A1 (el)
HR (1) HRP20120851T1 (el)
IL (1) IL188282A (el)
MA (1) MA29625B1 (el)
NO (1) NO20076663L (el)
NZ (1) NZ564567A (el)
PL (1) PL1899377T3 (el)
PT (1) PT1899377E (el)
SG (1) SG162829A1 (el)
SI (1) SI1899377T1 (el)
WO (1) WO2007003421A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5129122B2 (ja) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー 癌治療のための抗体およびグルココルチコイドの組み合わせ
CA2689941C (en) 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
DK2207808T3 (da) 2007-11-02 2013-08-05 Novartis Ag Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse
CA2730473A1 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
KR20210118085A (ko) 2018-12-21 2021-09-29 키맵 리미티드 공통 경쇄를 갖는 ＦＩＸａｘＦＸ 이중특이적 항체
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
WO2005061545A2 (en) * 2003-12-22 2005-07-07 Glaxo Group Limited Nogoa antibodies for the treatment of alzheimer disease

Also Published As

Publication number Publication date
IL188282A0 (en) 2008-04-13
HRP20120851T1 (hr) 2012-11-30
WO2007003421A2 (en) 2007-01-11
EA014291B1 (ru) 2010-10-29
CR9623A (es) 2008-04-10
PL1899377T3 (pl) 2013-01-31
SI1899377T1 (sl) 2012-12-31
AU2006265276A1 (en) 2007-01-11
NO20076663L (no) 2008-02-27
EP1899377A2 (en) 2008-03-19
MA29625B1 (fr) 2008-07-01
PT1899377E (pt) 2012-11-20
EA200702634A1 (ru) 2008-06-30
JP2009500363A (ja) 2009-01-08
NZ564567A (en) 2010-09-30
CA2614076A1 (en) 2007-01-11
AU2006265276B2 (en) 2011-10-13
SG162829A1 (en) 2010-07-29
DK1899377T3 (da) 2012-11-12
ES2391902T3 (es) 2012-11-30
BRPI0612734A2 (pt) 2010-11-30
IL188282A (en) 2011-04-28
WO2007003421A3 (en) 2007-04-12
KR20080030960A (ko) 2008-04-07
HK1115598A1 (en) 2008-12-05
EP1899377B1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
NL301089I2 (nl) imlifidase
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1118714T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2
CY1118369T1 (el) Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
TW200740844A (en) Novel MAdCAM antibodies
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201000424A1 (ru) Антитела к il-23
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
TR201000668T1 (tr) Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA201290322A1 (ru) Лечение желудочно-кишечных расстройств
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
CY1120436T1 (el) Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3